Replication study of GWAS risk loci in Greek multiple sclerosis patients

Hadjigeorgiou, Georgios M.; Kountra, Persia-Maria; Koutsis, Georgios; Tsimourtou, Vana; Siokas, Vasileios; Dardioti, Maria; Rikos, Dimitrios; Marogianni, Chrysoula; Aloizou, Athina‐Maria; Karadima, Georgia; Ralli, Styliani; Grigoriadis, Nikolaos; Bogdanos, Dimitrios P.; Πάνας, Μάριος; Dardiotis, Efthimios

doi:10.1007/s10072-018-3617-6

Cited by 27 publications

(15 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple sclerosis (MS) is an immune-mediated disease that affects the entire central nervous system (CNS) [1][2][3]. Magnetic resonance imaging (MRI) lesions are wellscattered at white matter (WM) and grey matter (GM) [4], while normal-appearing brain tissue in MRI also seems to be affected in pathological studies [4].…”

Section: Introductionmentioning

confidence: 99%

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Andravizou

Dardiotis

Artemiadis

et al. 2019

Autoimmun Highlights

Self Cite

114

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system characterized by focal or diffuse inflammation, demyelination, axonal loss and neurodegeneration. Brain atrophy can be seen in the earliest stages of MS, progresses faster compared to healthy adults, and is a reliable predictor of future physical and cognitive disability. In addition, it is widely accepted to be a valid, sensitive and reproducible measure of neurodegeneration in MS. Reducing the rate of brain atrophy has only recently been incorporated as a critical endpoint into the clinical trials of new or emerging disease modifying drugs (DMDs) in MS. With the advent of easily accessible neuroimaging softwares along with the accumulating evidence, clinicians may be able to use brain atrophy measures in their everyday clinical practice to monitor disease course and response to DMDs. In this review, we will describe the different mechanisms contributing to brain atrophy, their clinical relevance on disease presentation and course and the effect of current or emergent DMDs on brain atrophy and neuroprotection. which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

show abstract

Section: Introductionmentioning

confidence: 99%

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Andravizou

Dardiotis

Artemiadis

et al. 2019

Autoimmun Highlights

Self Cite

114

View full text Add to dashboard Cite

show abstract

“…Thus, studies on single-nucleotide polymorphisms (SNPs) and genome (GWAS) and transcriptome-wide association studies have revealed numerous possibly related SNPs and mechanistic clues [12][13][14]. Field synopses, as well as meta-analyses of GWAS, have also been reported (e.g., PDGene, AlzGene, and AlsGene) [15][16][17][18][19][20][21][22][23]. Nonetheless, as shown by updated study designs (phenome/ exposome/ environmentwide association studies), relevant statistical tools (e.g., mediation and multivariable Mendelian randomization), and epidemiological approaches (e.g., triangulation approaches [24]), this interplay has become even more complex because of the many confounders [25][26][27][28][29][30][31][32].…”

Section: Introductionmentioning

confidence: 99%

Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews

Mentis

Dardiotis

Efthymiou

et al. 2021

BMC Med

Self Cite

View full text Add to dashboard Cite

Background The etiologies of chronic neurological diseases, which heavily contribute to global disease burden, remain far from elucidated. Despite available umbrella reviews on single contributing factors or diseases, no study has systematically captured non-purely genetic risk and/or protective factors for chronic neurological diseases. Methods We performed a systematic analysis of umbrella reviews (meta-umbrella) published until September 20th, 2018, using broad search terms in MEDLINE, SCOPUS, Web of Science, Cochrane Database of Systematic Reviews, Cumulative Index to Nursing and Allied Health Literature, ProQuest Dissertations & Theses, JBI Database of Systematic Reviews and Implementation Reports, DARE, and PROSPERO. The PRISMA guidelines were followed for this study. Reference lists of the identified umbrella reviews were also screened, and the methodological details were assessed using the AMSTAR tool. For each non-purely genetic factor association, random effects summary effect size, 95% confidence and prediction intervals, and significance and heterogeneity levels facilitated the assessment of the credibility of the epidemiological evidence identified. Results We identified 2797 potentially relevant reviews, and 14 umbrella reviews (203 unique meta-analyses) were eligible. The median number of primary studies per meta-analysis was 7 (interquartile range (IQR) 7) and that of participants was 8873 (IQR 36,394). The search yielded 115 distinctly named non-genetic risk and protective factors with a significant association, with various strengths of evidence. Mediterranean diet was associated with lower risk of dementia, Alzheimer disease (AD), cognitive impairment, stroke, and neurodegenerative diseases in general. In Parkinson disease (PD) and AD/dementia, coffee consumption, and physical activity were protective factors. Low serum uric acid levels were associated with increased risk of PD. Smoking was associated with elevated risk of multiple sclerosis and dementia but lower risk of PD, while hypertension was associated with lower risk of PD but higher risk of dementia. Chronic occupational exposure to lead was associated with higher risk of amyotrophic lateral sclerosis. Late-life depression was associated with higher risk of AD and any form of dementia. Conclusions We identified several non-genetic risk and protective factors for various neurological diseases relevant to preventive clinical neurology, health policy, and lifestyle counseling. Our findings could offer new perspectives in secondary research (meta-research).

show abstract

“…A study using a similar methodology has been performed on vitiligo patients 42 . Disease-associated genetic loci shared between MS and vitiligo have been identified 40,43 . Individuals who carry the HLA-DRB1 gene may have an increased risk of developing both MS and vitiligo 44,45 .…”

Section: Discussionmentioning

confidence: 99%

Association of multiple sclerosis with vitiligo: a systematic review and meta-analysis

Shen

Chang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Polyautoimmunity implicates that some autoimmune diseases share common etiopathogenesis. Some studies have reported an association between multiple sclerosis (MS) and vitiligo; meanwhile, other studies have failed to confirm this association. We performed a systemic review and meta-analysis to examine the association of MS with vitiligo. We searched the MEDLINE and Embase databases on March 8, 2020 for relevant case–control, cross-sectional, and cohort studies. The Newcastle–Ottawa Scale was used to evaluate the risk of bias of the included studies. Where applicable, we performed a meta-analysis to calculate the pooled odds ratio (OR) for case–control/cross-sectional studies and risk ratio for cohort studies with 95% confidence interval (CI). Our search identified 285 citations after removing duplicates. Six case–control studies with 12,930 study subjects met our inclusion criteria. Our meta-analysis found no significant association of MS with prevalent vitiligo (pooled OR 1.33; 95% CI 0.80‒2.22). Analysis of the pooled data failed to display any increase of prevalent vitiligo in MS patients compared with controls. Ethnic and genetic factors may play an important role for sporadically observed associations between MS and vitiligo. Future studies of this association should therefore consider stratification by ethnic or genetic factors.

show abstract

Replication study of GWAS risk loci in Greek multiple sclerosis patients

Cited by 27 publications

References 39 publications

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews

Association of multiple sclerosis with vitiligo: a systematic review and meta-analysis

Contact Info

Product

Resources

About